We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urinary Stent with Unique Suture Design Could Reduce Hospital Readmissions and Replacement Costs

By HospiMedica International staff writers
Posted on 03 May 2022

Ureteral stents ease urine flow from the kidney to the bladder to prevent kidney damage caused by kidney stones, strictures or swelling of the ureter (which connects the kidney to the bladder). More...

Existing ureteral stents currently on the market have complication rates as high as 60%, causing significant patient pain and discomfort, including urine reflux, flank pain and bladder spasms, and leading to additional medical attention and replacement procedures. Urine reflux is well documented as a leading cause of pain and discomfort and can lead to kidney damage and kidney infections, which may require hospitalization. Now, a new urinary stent with a unique suture design allows the ureteral orifice to close naturally and reduce reflex of urine back into the kidney, thus offering the potential to reduce significantly these side effects and provides more effective management of patients suffering from kidney stones and other similar disorders.

The Relief Stent invented at University Hospitals (UH) in Cleveland (Cleveland, OH, USA) for patients suffering from kidney stones and other issues causing difficulty with drainage of the kidney has the potential to ease pain for millions of patients and reduce hospital costs. More than three million ureteral stent placements occur annually worldwide. The patented stent technology enables urine to flow past kidney stones, preventing urine retention, blood in urine, pain & irritation, and kidney damage. RELIEF increases patient comfort and improves hospital economic value by reducing readmission and replacement costs.

The new urinary stent conceived and invented by Lee Ponsky, MD, Chair of the Department of Urology and the Leo & Charlotte Goldberg Chair in Advanced Surgical Therapies at UH in Cleveland has secured FDA 510k clearance. Dr. Ponsky was able to take his idea, which was conceived in the operating rooms of UH, to a commercial-ready implantable device with the help of UH Ventures, the UH system’s commercialization arm. The Relief Stent has demonstrated early success in preclinical study cases being performed at UH.

“I developed the Relief Stent from not only my work as a physician, but also from the experience I had myself as a ureteral stent patient,” said Dr. Ponsky, who is a urological surgeon, “Using current stents is often painful for patients. The Relief Stent addresses the most significant side effects, reflux and bladder spasms, in a way that is quite intuitive, allowing the opening from the ureter into the bladder to remain closed during voiding and avoiding painful reflux up into the kidney.”

“This is a significant milestone for the Relief Stent which has potential to improve patient comfort and quality of life, while it also aims to improve hospital economics by reducing readmissions and replacement costs that will be part of post-market studies with this FDA clearance,” said Kyle Scarberry, MD, a urologist at UH who is the principal investigator of the Relief stent study.

Related Links:
University Hospitals (UH) in Cleveland 


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.